Market Overview

UPDATE: Argus Research Upgrades Stryker

Related SYK
Benzinga's Top Upgrades, Downgrades For August 16, 2018
10 Biggest Price Target Changes For Wednesday

In their Wednesday morning summary, Argus Research analysts upgraded shares of Stryker (NYSE: SYK) from Hold to Buy and set a price target of $102.

Looking at 2014, the Argus team is forecasting a stronger second half for Stryker. The team is basing this on the company's "solid" growth in businesses outside orthopedics, a better position to boost sales of knee implants following the MAKO acquisition and a higher amount of elective surgeries.

The team also noted that the pending merger of Zimmer and Biomet may create a possibility for Stryker to gain market share due potential disruptions of the competitor's sales.

Based on the items above, the analysts at Argus have raised their EPS estimates from $4.78 to $4.81 and $5.06 to $5.20 for 2014 and 2015, respectively.

Latest Ratings for SYK

Aug 2018BTIG ResearchInitiates Coverage OnBuy
Jul 2018BairdMaintainsOutperformOutperform
Jul 2018CitigroupMaintainsNeutralNeutral

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Argus ResearchAnalyst Color News Upgrades Price Target Analyst Ratings


Related Articles (SYK + ZMH)

View Comments and Join the Discussion!

Shares Of BioFuel Up +40% Following M&A Announcement

State Of The Economy Update: NFIB Small Business Optimism